Celldex Therapeutics (CLDX) News Today $23.55 -2.19 (-8.51%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Celldex Therapeutics (NASDAQ:CLDX) Reaches New 52-Week Low - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year Low - What's Next?November 15 at 2:29 PM | marketbeat.comSteven Cohen's Strategic Reduction in Celldex Therapeutics HoldingsNovember 15 at 8:01 AM | gurufocus.comAnthony S. Marucci Purchases 11,500 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) StockNovember 13, 2024 | insidertrades.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Up 4.2% After Insider Buying ActivityNovember 13, 2024 | americanbankingnews.comInsider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires SharesNovember 12, 2024 | gurufocus.comInsider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of StockCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) CEO Anthony S. Marucci purchased 11,500 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at $1,080,416.88. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.November 12, 2024 | marketbeat.comEquities Analysts Set Expectations for CLDX FY2024 EarningsNovember 12, 2024 | americanbankingnews.comCelldex Therapeutics to Present at Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comWhat is Leerink Partnrs' Forecast for CLDX FY2024 Earnings?November 11, 2024 | americanbankingnews.comHC Wainwright Has Positive Forecast for CLDX FY2024 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - HC Wainwright raised their FY2024 EPS estimates for Celldex Therapeutics in a report released on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($2.39) per sNovember 11, 2024 | marketbeat.comResearch Analysts Set Expectations for CLDX FY2024 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Leerink Partnrs dropped their FY2024 EPS estimates for shares of Celldex Therapeutics in a report released on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of ($2November 11, 2024 | marketbeat.comFY2028 Earnings Estimate for CLDX Issued By Leerink PartnrsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for shares of Celldex Therapeutics in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now anticipateNovember 8, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and oneNovember 8, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)November 7, 2024 | markets.businessinsider.comCelldex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low - Time to Sell?Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week Low - Time to Sell?November 5, 2024 | marketbeat.comEmerald Advisers LLC Acquires 257,773 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Emerald Advisers LLC increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 129.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 456,202 shares of the biopharmNovember 3, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 6% - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 6% - Time to Sell?October 29, 2024 | marketbeat.comCelldex’s Promising Phase 2 Results and Strong Financial Position Warrant a Buy RatingOctober 28, 2024 | markets.businessinsider.comCelldex selloff creates buying opportunity, says GuggenheimOctober 28, 2024 | markets.businessinsider.comCelldex Therapeutics' (CLDX) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 yearsOctober 28, 2024 | finance.yahoo.comCelldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible UrticariaOctober 27, 2024 | markets.businessinsider.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Lifted by Novo Holdings A SNovo Holdings A S lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 963,663 shares of the bioOctober 27, 2024 | marketbeat.comCelldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible UrticariaOctober 26, 2024 | globenewswire.comCelldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024October 25, 2024 | globenewswire.comCelldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical ResultsOctober 24, 2024 | msn.comCan This Growth Stock Deliver 135% Upside in 2025?October 23, 2024 | msn.comCelldex’s Barzolvolimab Outperforms Competitor in Chronic Inducible Urticaria Market, Justifying Buy RatingOctober 16, 2024 | markets.businessinsider.comCelldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap StocksOctober 16, 2024 | insidermonkey.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, six have given a buy rating and onOctober 14, 2024 | marketbeat.comCitigroup Initiates Coverage of Celldex Therapeutics (CLDX) with Buy RecommendationOctober 8, 2024 | msn.comCitigroup Begins Coverage on Celldex Therapeutics (NASDAQ:CLDX)Citigroup started coverage on Celldex Therapeutics in a report on Monday. They set a "buy" rating and a $70.00 price objective for the company.October 7, 2024 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 86.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,788 shares of the biopharmaceutical company's stock aftOctober 5, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5%Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5%October 2, 2024 | marketbeat.comAlgert Global LLC Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Algert Global LLC lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,614 shares of the biopharmaceuticalOctober 2, 2024 | marketbeat.comGoldman Sachs Initiates Coverage of Celldex Therapeutics (CLDX) with Neutral RecommendationOctober 2, 2024 | msn.comCelldex started by Goldman Sachs at neutral, lack of catalysts citedSeptember 30, 2024 | seekingalpha.comHold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive ChallengesSeptember 30, 2024 | markets.businessinsider.comNovo Holdings A S Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Novo Holdings A S bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 850,000 shares of the biopharmaceutical company's stoSeptember 30, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday. They set a "neutral" rating and a $45.00 price target for the company.September 30, 2024 | marketbeat.comD. E. Shaw & Co. Inc. Raises Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)D. E. Shaw & Co. Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 47.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 845,560 shares of the biopharmaceutical company's stock after purchasing anSeptember 29, 2024 | marketbeat.comWolfe Research Downgrades Celldex Therapeutics (CLDX)September 28, 2024 | msn.comBuy Rating Affirmed: Celldex’s Barzolvolimab Shows Promising Long-Term Efficacy in CSU TreatmentSeptember 27, 2024 | markets.businessinsider.comCelldex (CLDX) Receives a Buy from TD CowenSeptember 27, 2024 | markets.businessinsider.comWolfe Research Lowers Celldex Therapeutics (NASDAQ:CLDX) to Peer PerformWolfe Research lowered Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday.September 27, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Upgraded by Wells Fargo & Company to Strong-BuyWells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday.September 27, 2024 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday.September 26, 2024 | marketbeat.comPoint72 Asset Management L.P. Boosts Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Point72 Asset Management L.P. boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 51.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,937,991 shares of the biopharmaceutical company'sSeptember 26, 2024 | marketbeat.comCelldex stock tumbles 18% amid Phase 2 data release for barzolvolimab (update)September 26, 2024 | msn.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.390.55▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼204▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intellia Therapeutics News Aspira Women's Health News Neogen News Riot Platforms News Lantheus News Halozyme Therapeutics News Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts